ANIP rare disease and generics growth drives revenues past $1B
The company says rare-disease products such as Cortrophin Gel and its generics business have driven revenue over $1B, with an outlook supported by durable IP and capital allocation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.